Group 1 - The company held its ninth meeting of the fifth board of directors on February 11, 2026, with all six directors present, and the meeting was conducted in accordance with relevant regulations [2][3]. - The board approved the termination of the 2025 A-share issuance to specific targets and the withdrawal of the application documents due to changes in the macroeconomic environment and capital market conditions [3][19]. - The decision to terminate the issuance was made after thorough communication and analysis with relevant parties, and the company will continue to monitor capital market dynamics for future financing needs [21][22]. Group 2 - The board also approved the signing of a termination agreement with Shanghai Daoyun Asset Management Co., which was the intended subscriber for the A-share issuance [4][9]. - The termination agreement confirms that there are no disputes or potential disputes between the parties regarding the original subscription agreement, and it will not adversely affect the company's daily operations [13][15]. - The independent directors expressed that the termination of the A-share issuance is a prudent decision that complies with legal regulations and does not harm the interests of shareholders, especially minority shareholders [16][23].
天域生物科技股份有限公司 第五届董事会第九次会议决议公告